Clinical Trial

Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

Completed
View on ClinicalTrials.gov →
Summary
Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcomes will be collected.
Protocol Amendment History 2 changes
critical Trial completed 2026-07-15
minor Completion pushed: 2026-05-31 -> 2026-06-30 2026-05-29
Trial Details
NCT Number NCT07297238
Lead Sponsor Jinling Hospital, China
Conditions Short Bowel Syndrome (SBS), Intestinal Failure
Enrollment 20 participants
Start Date 2026-01-24
Primary Completion 2026-05-27 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-14